DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
66	IgA腎症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04287985 (ClinicalTrials.gov)	July 20, 2020	10/2/2020	Safety and Efficacy Study of VIS649 for IgA Nephropathy	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy	Immunoglobulin A Nephropathy;Glomerular Disease;IgAN	Drug: Dose-Placebo;Drug: Low Dose-VIS649;Drug: Medium Dose-VIS649;Drug: High Dose-VIS649	Visterra, Inc.	NULL	Recruiting	18 Years	N/A	All	144	Phase 2	United States;Japan;Korea, Republic of;Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04287985
(ClinicalTrials.gov)

July 20, 2020

10/2/2020

Safety and Efficacy Study of VIS649 for IgA Nephropathy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants With Immunoglobulin A (IgA) Nephropathy

Immunoglobulin A Nephropathy;Glomerular Disease;IgAN

Drug: Dose-Placebo;Drug: Low Dose-VIS649;Drug: Medium Dose-VIS649;Drug: High Dose-VIS649

Visterra, Inc.

NULL

Recruiting

18 Years

N/A

All

144

Phase 2

United States;Japan;Korea, Republic of;Spain